Updated July 2026. Tracking Nipah virus (NiV) vaccine development for outbreak preparedness against this emerging zoonotic threat with 40-75% case fatality rate. First identified in Malaysia 1998, Nipah causes severe encephalitis and respiratory disease with no approved treatment or vaccine. Transmitted from fruit bats to humans directly or via pigs, with documented human-to-human transmission. WHO priority pathogen. 2025-2026 highlights: Oxford ChAdOx1 NipahB became the world's first Nipah vaccine candidate to enter Phase 2 (Bangladesh, late 2025); EMA granted PRIME designation in June 2025; CEPI/Oxford/Serum Institute of India are building a 100,000-dose investigational ready reserve (announced October 2025). Moderna's mRNA-1215 Phase 1 results were published in Nature Medicine on March 12, 2026 (40 healthy adults, safe and immunogenic). PHV02 (VSV-vectored, Public Health Vaccines LLC) launches Phase 2 in Bangladesh early 2026. This tracker monitors outbreak preparedness vaccines for healthcare workers, at-risk populations in endemic regions (Bangladesh, India, Malaysia), and rapid response stockpiles.
Nipah virus is a WHO Blueprint priority pathogen with pandemic potential. Case fatality rate 40-75%, no approved vaccine or treatment, documented human-to-human transmission, and spillover events occurring annually in South Asia.
📊 View all Nipah vaccine trials on ClinicalTrials.gov →
🌍 CDC Nipah Virus Information →
🌍 WHO Nipah Virus Resources →
🌍 CEPI Nipah Vaccine Portfolio →
📰 Latest Nipah Vaccine News (Google News) →